British drugmaker will acquire Alexion for approximately $39bn

New company will focus on developing bispecific antibodies for rare bleeding disorders

Final appraisal determination recommends anti-VEGF treatment for NHS use

Surveys uncovers findings pre- and post-pandemic

Updated Date: Tue, 08 Dec 2020 00:00:00 EST

Updated Date: Tue, 08 Dec 2020 00:00:00 EST

Updated Date: Tue, 08 Dec 2020 00:00:00 EST

Updated Date: Tue, 08 Dec 2020 00:00:00 EST

Updated Date: Tue, 08 Dec 2020 00:00:00 EST

In an age of social media outrage, it is hardly surprising that hospital staff dressed in full personal […]